1. Home
  2. TBPH vs DAO Comparison

TBPH vs DAO Comparison

Compare TBPH & DAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.86

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Youdao Inc. each representing one

DAO

Youdao Inc. each representing one

HOLD

Current Price

$10.18

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
DAO
Founded
2013
2006
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
TBPH
DAO
Price
$13.86
$10.18
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$18.50
N/A
AVG Volume (30 Days)
782.6K
75.8K
Earning Date
05-07-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.88
N/A
Revenue
$15,386,000.00
N/A
Revenue This Year
$70.90
$12.15
Revenue Next Year
N/A
$14.03
P/E Ratio
$15.75
$72.35
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$6.30
52 Week High
$21.03
$12.96

Technical Indicators

Market Signals
Indicator
TBPH
DAO
Relative Strength Index (RSI) 27.74 50.59
Support Level $13.41 $10.09
Resistance Level $14.76 $10.33
Average True Range (ATR) 0.58 0.47
MACD -0.08 0.03
Stochastic Oscillator 11.29 40.83

Price Performance

Historical Comparison
TBPH
DAO

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About DAO Youdao Inc. each representing one

Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.

Share on Social Networks: